Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Metrics to compare | PBDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPBDAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 30.1x | −3.8x | −0.7x | |
PEG Ratio | 0.22 | 0.06 | 0.00 | |
Price/Book | 3.8x | 2.7x | 2.6x | |
Price / LTM Sales | 3.1x | 61.4x | 3.4x | |
Upside (Analyst Target) | - | 246.9% | 39.1% | |
Fair Value Upside | Unlock | 6.2% | 5.5% | Unlock |